Squarepoint Ops LLC increased its position in shares of Global Medical REIT Inc (NYSE:GMRE) by 69.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,349 shares of the company’s stock after acquiring an additional 33,357 shares during the period. Squarepoint Ops LLC owned approximately 0.22% of Global Medical REIT worth $927,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its holdings in Global Medical REIT by 186.6% during the third quarter. Tower Research Capital LLC TRC now owns 4,443 shares of the company’s stock worth $51,000 after acquiring an additional 2,893 shares during the period. Financial Advantage Inc. grew its holdings in Global Medical REIT by 47.6% during the third quarter. Financial Advantage Inc. now owns 4,795 shares of the company’s stock worth $54,000 after acquiring an additional 1,546 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Global Medical REIT by 64.1% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,746 shares of the company’s stock worth $60,000 after acquiring an additional 2,245 shares during the period. Nisa Investment Advisors LLC grew its holdings in Global Medical REIT by 19.7% during the third quarter. Nisa Investment Advisors LLC now owns 9,506 shares of the company’s stock worth $108,000 after acquiring an additional 1,562 shares during the period. Finally, Corrado Advisors LLC acquired a new position in Global Medical REIT during the third quarter worth about $122,000. 49.58% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts recently issued reports on GMRE shares. TheStreet raised Global Medical REIT from a “c+” rating to a “b-” rating in a report on Monday, October 14th. Zacks Investment Research lowered Global Medical REIT from a “buy” rating to a “hold” rating in a report on Saturday, November 9th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $11.01.

NYSE:GMRE opened at $12.81 on Friday. The business’s 50-day moving average price is $12.89 and its 200 day moving average price is $11.41. The firm has a market cap of $475.99 million, a P/E ratio of 16.42 and a beta of 0.46. Global Medical REIT Inc has a 52-week low of $8.15 and a 52-week high of $14.26. The company has a quick ratio of 0.13, a current ratio of 0.13 and a debt-to-equity ratio of 1.25.

Global Medical REIT (NYSE:GMRE) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.02 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.17). The company had revenue of $18.20 million during the quarter, compared to analysts’ expectations of $17.68 million. Global Medical REIT had a return on equity of 5.49% and a net margin of 23.42%. Sell-side analysts expect that Global Medical REIT Inc will post 0.75 EPS for the current year.

Global Medical REIT Company Profile

Global Medical REIT, Inc engages in the acquisition of purpose-built healthcare facilities and leasing of those properties to strong healthcare systems and physician groups. The company was founded on March 18, 2011 and is headquartered in Bethesda, MD.

Recommended Story: Average Daily Trade Volume – ADTV

Want to see what other hedge funds are holding GMRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Medical REIT Inc (NYSE:GMRE).

Institutional Ownership by Quarter for Global Medical REIT (NYSE:GMRE)

Receive News & Ratings for Global Medical REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Medical REIT and related companies with MarketBeat.com's FREE daily email newsletter.